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GPR84 is a member of the metabolic G protein-coupled receptor family, and its expres-
sion has been described predominantly in immune cells. GPR84 activation is involved 
in the inflammatory response, but the mechanisms by which it modulates inflammation 
have been incompletely described. In this study, we investigated GPR84 expression, 
activation, and function in macrophages to establish the role of the receptor during 
the inflammatory response. We observed that GPR84 expression in murine tissues is 
increased by endotoxemia, hyperglycemia, and hypercholesterolemia. Ex vivo studies 
revealed that GPR84 mRNA expression is increased by LPS and other pro-inflammatory 
molecules in different murine and human macrophage populations. Likewise, high glu-
cose concentrations and the presence of oxidized LDL increased GPR84 expression in 
macrophages. Activation of the GPR84 receptor with a selective agonist, 6-(octylamino) 
pyrimidine-2,4(1H,3H)-dione (6-n-octylaminouracil, 6-OAU), enhanced the expression of 
phosphorylated Akt, p-ERK, and p65 nuclear translocation under inflammatory con-
ditions and elevated the expression levels of the inflammatory mediators TNFα, IL-6, 
IL-12B, CCL2, CCL5, and CXCL1. In addition, GPR84 activation triggered increased 
bacterial adhesion and phagocytosis in macrophages. The enhanced inflammatory 
response mediated by 6-OAU was not observed in GPR84−/− cells nor in macrophages 
treated with a selective GPR84 antagonist. Collectively, our results reveal that GPR84 
functions as an enhancer of inflammatory signaling in macrophages once inflammation is 
established. Therefore, molecules that antagonize the GPR84 receptor may be potential 
therapeutic tools in inflammatory and metabolic diseases.
Keywords: immunometabolism, inflammation, metabolic g protein-coupled receptors, gPr84, macrophages
Abbreviations: 6-OAU, 6-(octylamino) pyrimidine-2,4(1H,3H)-dione/6-n-octylaminouracil; ApoE−/−, apolipoprotein 
E knockout; BMDMs, bone marrow-derived macrophages; cAMP, cyclic AMP; CI, Cell Index; DAG, diacylglycerol; DIM, 
diindolylmethane 2,; FBS, fetal bovine serum; FFAs, free fatty acids; GPCR, G protein-coupled receptor; GPR84-CHO, CHO 
cells transfected with the human GPR84 receptor; HFD, high-fat diet; hMDMs, human monocyte-derived macrophages; i.p., 
intraperitoneal; IP3, inositol triphosphate; MCFA, medium chain fatty acid; NFκB, nuclear factor κB; NOD, non-obese dia-
betic; PAMPs, pathogen-associated molecular patterns; PTX, pertussis toxin; PMNs, polymorphonuclear leukocytes; PBMC, 
peripheral blood mononuclear cells; TBS-T, tris-buffered saline with Tween.
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inTrODUcTiOn
The concept of immunometabolism was first described in 2011, 
and it has emerged as a new field of scientific study (1). It high-
lights the regulatory interactions between innate and adaptive 
immunity and metabolism and provides new insights into disease 
mechanisms with the potential to identify new targets for thera-
peutic intervention (2, 3).
Macrophages are innate immune cells that play a pivotal role 
during the inflammatory response, acting as cellular mediators 
of both acute and chronic inflammation (4). Macrophages can 
be of bone marrow origin or can be tissue-resident macrophages 
derived from fetal monocytes (5). Their major functions include 
phagocytosis, antigen presentation, and immunomodulation 
through the production of cytokines, chemokines, and other 
inflam matory mediators. They are critical cells in the initiation, 
maintenance, and resolution of inflammation and hence are 
interesting to target in inflammatory disease (6).
Within the G protein-coupled receptor (GPCR) superfam-
ily, a subset of metabolite-sensing GPCRs has been shown to 
actively participate in inflammation during metabolic disease. 
They have been reported to respond to intermediates of energy 
metabolism including free-fatty acids, lactate, succinate, and 
ketone bodies, among others (3, 7). GPCRs are seven trans-
membrane domain receptors that couple to heterotrimeric 
G proteins (Gαi, Gαs, Gαq, Gα12/13) and/or β-arrestins. These 
GPCRs regulate the activity of secondary-messenger produc-
ing enzymes or ion channels, modulating the intracellular 
concentrations of inositol triphosphate (IP3), diacylglycerol, 
cyclic AMP (cAMP), or calcium, among others. Consequently, 
they regulate the downstream intracellular signaling of kinase 
cascades, such as ERK/MAPK, JNK, p38, and Akt/PI3K. These 
pathways are central to the control of cell proliferation, dif-
ferentiation, survival, migration, and other essential biological 
functions (3, 8, 9).
The GPR84 receptor was first identified in 2001, and it couples 
to the Bordetella pertussis toxin-sensitive Gαi protein, which 
inhibits adenylate cyclase activity (10, 11). Several studies have 
characterized GPR84 as a medium chain fatty acid (MCFA) 
receptor, with capric acid (a 10-carbon chain fatty acid) being 
the most potent ligand (11). However, GPR84 is not officially 
a “deorphanized” receptor, yet, as there is not a consensus that 
MCFAs are the major endogenous ligands that activate GPR84 
(12). Numerous studies have focused their attention on devel-
oping new GPR84 agonist compounds with improved potency, 
selectivity, and specificity. 6-n-octylaminouracil 4 (6-OAU) was 
first reported by Suzuki et al. to be a novel GPR84-specific tool 
compound with far greater potency than hydroxylated or native 
MCFAs (EC50 values of ~500 nM for 6-OAU versus ~4 μM for 
capric acid in transfected GPR84-CHO cells) (13). Other small 
molecule screening programmes have identified further agonists 
that are active at the human GPR84 receptor expressed in trans-
fected cell systems (14–16). However, these compounds have not 
been tested in relevant primary cell types.
A potential role for GPR84 in the regulation of inflammation 
has been suggested by several authors. It has previously been 
reported that the GPR84 agonist, diindolylmethane 2 (DIM), 
amplified IL-12 p40 mRNA expression in the LPS-stimulated 
RAW 264.7 macrophage cell line (11). Furthermore, GPR84 was 
shown to promote chemotaxis and pro-inflammatory cytokine 
release in human polymorphonuclear leukocytes and mac-
rophages (13). In the context of metabolic disease, it has been 
suggested that GPR84 may influence lipid metabolism, as, com-
pared to normal mice, GPR84-deficient mice exhibited smaller 
livers and increased triglyceride accumulation in response to 
FFA diet (17).
In this study, we aimed to identify the molecular and cel-
lular responses following GPR84 activation in macrophages. 
We report that GPR84 expression is upregulated in macro phages 
by endotoxemia, hyperglycemia, and hypercholesterolemia. 
Therefore, we investigated intracellular signaling following GPR84 
activation. We found that the synthetic GPR84 agonist 6-OAU 
upregulated the Akt, ERK, and the nuclear factor κB (NFκB) 
signaling pathways, amplified the expression of inflammatory 
mediators, and increased bacterial adhesion and phagocytosis 
in murine pro-inflammatory macrophages. None of these effects 
were observed in macrophages derived from GPR84 deficient 
mice or macrophages pretreated with a synthetic GPR84-
specific antagonist.
MaTerials anD MeThODs
Materials
All cell culture media, buffers, and other laboratory chemicals 
were obtained from Sigma-Aldrich (Gilligham, UK) unless 
otherwise specified. Pam3CysK and purified LPS were pur-
chased from InVivogen (San Diego, CA, USA). Cytokines and 
chemokines were purchased from Peprotech (London, UK) and 
R&D Systems (Abingdon, UK). CIM-plate 16 and E-plate 96 PET 
were purchased from ACEA Biosciences (San Diego, CA, USA). 
pH-rodo Green E. coli Bioparticles conjugated for phagocytosis 
were obtained from ThermoFisher Scientific (Loughborough, 
UK). Rabbit anti-phospho-ERK (D13.14.4E), rabbit anti-total-
ERK, rabbit anti-phospho-Akt (D9E), rabbit anti-total-Akt, 
β-actin, were purchased from Cell Signaling Technologies 
(Danvers, MA, USA). Mouse anti-p-65 was obtained from Santa 
Cruz Biotechnology (Dallas, TX, USA) and rabbit anti-GPR84 
antibodies were from Santa Cruz Biotechnology and from Bioss 
Antibodies (Woburn, MA, USA). Rabbit anti-histone-H3 and 
mouse anti-tubulin were purchased from AbCam (Cambridge, 
UK). HRP-conjugated secondary antibodies and Bio-gel 
polyacrylamide beads were obtained from Biorad Laboratories 
(Hemel Hempstead, UK). Donkey anti-mouse Alexa Fluor 
488 was obtained from ThermoFisher Scientific. Recombinant 
Mouse Complement Component C5a Protein was purchased 
from R&D Systems (Abingdon, UK). Pertussis toxin (PTX), a 
selective Gi-coupled signaling inhibitor, was purchased from 
ThermoFisher Scientific. 6-OAU was purchased from AstaTech 
(Bristol, PA, USA). The GPR84 antagonist, first described in a 
patent from Galapagos NV Company (US 2013/0165437 A1), was 
synthesized in-house as described in the supplementary methods. 
Both compounds were dissolved in 100% DMSO and then diluted 
in cell media to reach their respective working concentrations in 
0.3% DMSO.
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animals
All animal studies were conducted with ethical approval from 
the Dunn School of Pathology Local Ethical Review Committee 
and in accordance with the UK Home Office regulations 
(Guidance on the Operation of Animals, Scientific Procedures 
Act, 1986).
Male (7–10  weeks) C57BL/6 mice were obtained from the 
Biomedical Services Unit (Oxford, UK). Breeding pairs of 
non-obese diabetic (NOD) mice on a NOD/ShiLtJ background 
were originally obtained from Charles River (Calco, Italy), 
and their offspring were inter-crossed to provide mice for this 
experiment. Apolipoprotein E knockout (ApoE−/−) mice were 
purchased from Charles River. GPR84tm1.1 (KOMP) Vlcg sperm 
was obtained from the KOMP Repository at UC Davis. Hete-
rozygous mice were re-derived through in  vitro fertilization at 
Mary Lyon Center, MRC Harwell on a C57BL6/N background. 
Generated heterozygous mice were further bred to generate WT 
and Gpr84−/− mice. All mice were housed in a 12-h light/12-h 
dark cycle unit with free access to food and water.
In Vivo studies and Tissue collection
Protocol I. Endotoxemia Model
Male C57BL/6 mice were injected intraperitoneally (i.p.) with 
1  mg/kg LPS or PBS and were monitored until sacrifice 2 and 
8 h post injection.
Protocol II. Diabetes Model
For diabetic mice experiments, the autoimmune type 1 diabetes 
model of NOD mice was used. Female 11- to 15-week-old mice 
were monitored weekly for glycosuria from 9 to 10 weeks of age 
until the onset of diabetes. Once they were detected as being dia-
betic by presence of glucose in the urine, animals were sacrificed 
and tissues were harvested for analysis. Non-diabetic NOD mice 
of same age were used as littermate controls for the study.
Protocol III. Atherosclerosis Model
For the in vivo hypercholesterolemia experiments, male 10-week-
old ApoE−/− mice were fed on a Western type high-fat diet 
[high-fat diet (HFD), 21% milk fat, 0.15% cholesterol, SDS Diets, 
Essex, UK] for 6 or 12 weeks and then sacrificed to harvest tissues. 
ApoE−/− mice fed a regular chow diet were used as controls.
All animals were euthanized via asphyxiation with a rising 
concentration of CO2. The brain, fat pads, lungs, kidneys, colon, 
bone marrow, and aorta were harvested and weighed before RNA 
or protein isolation.
Fluorescent-activated cell sorting (Facs)
For determining which cell types were expressing high levels of 
Gpr84 mRNA in the model of endotoxemia, bone marrow was 
harvested from PBS/LPS injected mice, and bone marrow cells 
were harvested. A single cell suspension was prepared followed 
by blockade of Fc receptors with a blocking antibody (2.4G2 
BD Biosciences, UK). In the presence of the blocking antibody, 
cells were stained for surface markers CD11b (Clone M1/70 
BioLengend), LyG6 (Clone 1A8 BD Biosciences, UK), and Ly6C 
(Clone HK1.4 BioLengend). Cell sorting was preformed using a 
BD FACSAria III (BD Biosciences, UK).
cell culture
Murine Bone Marrow-Derived Macrophages 
(BMDMs)
Bone marrow-derived macrophages were generated as previ-
ously described (18). Briefly, fresh bone marrow cells from 
tibiae and femurs of male C57BL/6 and GPR84−/− mice were 
isolated and cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 10% L929 cell-conditioned media as a source of 
macrophage colony-stimulating factor (19), and 1% penicillin/
streptomycin for 7  days. Bone marrow cells were seeded into 
8  ml of medium in 100  mm non-tissue culture treated Petri 
dishes (Thermo Fisher Scientific, Sterilin, UK). On day 5, an 
additional 5  ml of medium was added. Gentle scrapping was 
used to lift cells off dish surface. BMDMs were then counted and 
resuspended in FBS-free media at the desired cell concentration 
for the different experiments.
Biogel Elicitation of Primary Mouse Macrophages
Adult male C57BL/6 mice were injected i.p. with 1 ml of sterile 2% 
bio-gel polyacrylamide beads (P100 fine 45–90 µm) suspended in 
PBS. Mice were sacrificed 4 days later, and the elicited cells were 
collected by peritoneal lavage with 10  ml ice-cold PBS/2  mM 
EDTA. Cells were pelleted by centrifugation, resuspended in 
DMEM 10% FBS, and plated for 2–4 h to allow macrophages to 
attach to the plate and then were treated for experiments. Cells 
after the seeding have been previously demonstrated to be highly 
enriched for macrophages (20).
Resident Peritoneal Macrophages
Male C57BL/6 mice were sacrificed and peritoneal cavities were 
lavaged with 10 ml ice-cold PBS supplemented with 2 mM EDTA. 
Cells were pelleted by centrifugation, resuspended in DMEM 
10% FBS, and plated for 2–4 h to allow macrophages to attach 
to the plate.
Murine Microglia
Meninges were removed from brains of C57BL/6 mice at 
postnatal days 1–3. Trypsin 0.25% and DNase I were used for 
mincing the cerebral tissue, which was filtered and resuspended 
in DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin, and seeded in culture flasks. After 10–12 days in 
culture, detached microglia were collected and plated on 6-well 
culture dishes (21).
human Monocyte-Derived Macrophages 
(hMDMs)
Peripheral blood mononuclear cells (PBMCs) were purified from 
healthy human volunteers by density centrifugation of fresh 
peripheral blood over Ficoll-Paque PLUS (GE Healthcare Life 
Sciences, Piscataway, NJ, USA). Written consent was obtained from 
healthy individual (Ethical approval: South Central-Hampshire B, 
reference 13/SC/0392). The PBMC layer was carefully harvested 
and then washed repeatedly with PBS and centrifugation until the 
supernatant became clear. CD14+ monocytes were then isolated 
from the PBMCs by positive selection using magnetic beads 
conjugated to anti-CD14 antibody (Miltenyi Biotec, Bergisch 
Table 1 | Compounds and their final working concentrations used.
compound Working concentration
cLPS 100 ng/ml
pLPS 100 ng/ml
Pam3CysK 300 ng/ml
IFNγ 20 ng/ml
IL4 20 ng/ml
IL13 20 ng/ml
Zymosan 10 µg/ml
Poly I:C 10 µg/ml
Flagellin 500 ng/ml
oxLDL 50 µg/ml
C5a 10 nM
Pertussis toxin 200 ng/ml
6-OAU 1 µM
GPR84 Antagonist 10 µM
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Gladbach, Germany). Cells were maintained in RPMI 1640 
medium supplemented with 10% FBS, 50  ng/ml macrophage 
colony-stimulating factor (M-CSF, eBioscience, San Diego, CA, 
USA), 50 U/ml penicillin, and 50 µg/ml streptomycin for 7 days.
cell Treatments
Cells were seeded onto tissue culture plastic in FBS-free media 
and allowed to adhere overnight at 37°C, 5% CO2. Cells were then 
treated with compounds at concentrations indicated in Table 1.
For the glucose shock experiments, BMDMs were grown in 
low glucose (5.5 mM) DMEM supplemented with 10% FBS, 10% 
L929 cell conditioned medium, and 1% penicillin/streptomycin 
for 7 days prior to stimulation with 25 mM d-glucose or l-glucose 
for 4 h.
intracellular caMP Measurement
Intracellular cAMP levels were measured using the DiscoverX 
HitHunter® Assay (Birmingham, UK) following the manu-
facturer’s protocol. Briefly, CHO-K1 cells stably expressing 
human GPR84 receptor were plated into a 1/2 area 96-well 
plate (15,000  cells/well) and incubated at 37°C, 5% CO2 for 
24 h before the medium was removed and replaced with PBS. 
In agonist mode, the cells were simultaneously treated with 
25 µM forskolin and 6-OAU or vehicle for 30 min at 37°C, 5% 
CO2. In antagonist mode, the cells were pretreated with the 
antagonist or vehicle for 15 min, before stimulation with for-
skolin and 6-OAU at the EC80 concentration for 30 min at 37°C, 
5% CO2. Cell lysis and cAMP detection were performed as per 
the manufacturer’s protocol. Luminescence measurements were 
taken using a PHERAstar FS microplate reader (BMG Labtech, 
Aylesbury, UK).
ecis 96-Well assay
Wells of a 96-well ACEA E-plate were filled with 50 µl of media 
(RPMI + 25 mM HEPES) and a background signal was meas-
ured using the ACEA RTCA-SP system. Afterward, BMDMs 
(with or without LPS 0.1  µg/ml) were added to each well 
(50 µl = 50,000 cells/well) and left for 16 h at 37°C, 5% CO2, with 
Cell Index (CI) measurements made every 15  min. Cells were 
then treated with: vehicle (DMSO 0.3%); C5a (10 nM); 6-OAU 
(0.1–100 μM); capric acid (5–500 μM); lauric acid (5–500 μM); 
and undecanoic acid (5–500 μM). CI measurements were taken 
every 10 s for 3 h after compound addition. Data are displayed 
as change in CI from the point of compound addition (Δ Cell 
Index).
chemotaxis assay
Real-time chemotaxis experiments were performed as described 
previously using the ACEA xCELLigence RTCA-DP instrument 
(22). Briefly, vehicle (0.3% DMSO), 10 nM C5a, or 1 µM 6-OAU 
was added dissolved in media (RPMI  +  25  mM HEPES) to 
the lower chamber of a CIM-16 plate (160 µl/well). The upper 
chamber was attached and upper wells were filled with 50 µl of 
media following equilibration for 30  min. Then, the plate was 
transferred into the RTCA-DP system and the background signal 
was measured. BMDMs were then placed into the upper wells 
(50  µl–1 ×  105  cells/well). CI measurements were taken every 
5 s over 6 h. Chemotactic responses were assessed by quantifi-
cation of the slope of the curve in the first 90  min and by the 
maximum CI minus minimum CI (Max–Min) values of the curve 
over the entire experiment. Pooled data are displayed as a fold 
change relative to cells migrating toward vehicle alone.
Migration scratch assay
The scratch assay is an easy, low-cost, and well-developed method 
to measure cell migration in  vitro (23). BMDMs at 90–95% 
confluency were treated with either vehicle (0.3% DMSO) or 
1 µM 6-OAU for 1 h, followed by a scratch injury in the mid-
dle of the well using a plastic P10 Gilson pipette tip. Cells were 
then stimulated ± 10 nM C5a and immediately placed into the 
IncuCyte Zoom platform at 37°C, 5% CO2. Images were taken 
every 4 for 24 h, and cell migration was quantified by counting the 
number of cells that had invaded the scratch at 24 h, considering 
the reference area at time 0 h.
bacterial adhesion assay
E. coli strain DH5-α was cultured for 16 h in 5 ml LB broth at 37°C 
with shaking at 180 rpm, and a sub-culture was then prepared and 
grown for a further 3 h. Bacteria grown in exponential phase were 
adjusted to OD600 = 0.3 in DMEM containing 1% FBS (for DH5-
α, a suspension at OD600 = 0.3 corresponds to 2.28e8 CFU/mL).
Medium with a bacterial suspension (MOI =  5) was added 
to BMDMs (1 ×  105  cells/well) previously treated with vehicle 
(DMSO 0.3%), 1  µM 6-OAU, or 10  µM antagonist  +  1  µM 
6-OAU. The cell plate was centrifuged at 300 g for 5 min, and then 
incubated for 30 min at 37°C before wells were washed with PBS 
three times. To measure bacteria attached to the macrophages, 
cells were lysed with 200 µl of 1% triton-X for 2 min, and then 
diluted by addition of 800 µl of PBS. Serially diluted cell lysates 
were plated on LB agar plates for 16 h, and colony forming units 
were counted.
Phagocytosis assay
IncuCyte Zoom Phagocytosis
Bone marrow-derived macrophages previously treated with either 
vehicle (0.3% DMSO) or 1 µM 6-OAU for 1 h were incubated 
with unopsonised pHrodo E. coli bioparticles at 0.1 mg/ml in a 
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96-well flat clear bottom plate. For the inhibition studies with a 
GPR84 antagonist, cells were pretreated with 10 µM antagonist for 
30 min before addition of either vehicle or 6-OAU. The plate was 
then placed into the IncuCyte Zoom platform (Essen Bioscience, 
Welwyn Garden City, UK) which was housed inside a humidified 
incubator at 37°C, 5% CO2. Two to four images per well from 
three technical replicates were taken every 15 min for 4 h using a 
20× objective lens and then analyzed using the IncuCyte™ Basic 
Software. Green channel acquisition time was 400 ms.
Bead Phagocytosis
Bone marrow-derived macrophagess previously treated with 
either vehicle (0.3% DMSO) or 1 µM 6-OAU for 1 h in 4-well 
chamber slides (Thermo Fisher Scientific) were incubated with 
opsonized 3 µm polystyrene micro particle beads (Sigma-Aldrich) 
for 1  h at 37°C, 5% CO2. Bead opsonization was performed 
preincubating the beads with human serum (1:10 dilution in 
bead solution) for 1 h at 37°C, 5% CO2. Cells were then washed 
with PBS and fixed with methanol followed by staining with 
safranin (Sigma-Aldrich). After several PBS washes, the cham-
ber was disassembled and the slide was mounted with a cover 
slip using mounting media (Fluormount-G®, SouthernBiotech, 
Birmingham, AL, USA). Twenty images per well were taken using 
a Chromyx HD camera connected to ta Leica DME light micro-
scope. Number of beads was manually counted by an observer 
blind to cell treatments.
mrna expression analysis
Mouse tissues and cultured cells were extracted with TRIzol 
reagent (Thermo Fisher Scientific), and total RNA concentra-
tion and quality was determined with a ND-1000 spectropho-
tometer (Nano Drop Technologies, Wilmington, DE, USA). 
cDNA was synthesized from 700 to 1,000  ng RNA using the 
QuantiTect Reverse Transcription kit (Qiagen, Manchester, 
UK) according to the manufacturer’s instructions. Real-time 
quantitative PCR was performed using either Taqman or Sybr 
Select gene expression master mix (Life Technologies) in the 
StepOnePlus™ thermal cycler (Applied Biosystems). Primers 
were purchased from Qiagen (tnfα, il-6, il-12b, ccl2, ccl5, cxcl1, 
fcγRI, icam-1, βactin) and Taqman (gpr84, βactin). Cycle thresh-
old values were determined by the StepOne software and target 
gene expression was normalized to housekeeping gene (βactin). 
Relative expression results were plotted as mRNA expression 
divided by actin expression, and normalized to basal samples 
when convenient (24).
Protein expression analysis
Western Blot
Cells were lysed by adding RIPA buffer (Sigma-Aldrich) sup-
plemented with protease and phosphatase inhibitors (Sigma-
Aldrich) followed by manual disruption. BMDMs were separated 
into cytoplasmic and nuclear fractions following manufacturer’s 
protocol of the Subcellular Protein Fractionation kit from Thermo 
Scientific. Protein concentration was determined by using a 
BCA protein assay kit (Thermo Fisher Scientific). Total cell 
protein (20–30 mg) was added to 4× Laemmli buffer (250 mM 
Tris–HCl, pH 6.8, 8% SDS, 40% glycerol, 0.004% bromophenol 
blue, 20% b-mercaptoethanol) and heated at 95°C for 5  min. 
Samples were then resolved on SDS-PAGE gels and transferred 
onto Hybond ECL nitrocellulose membranes (GE Healthcare, 
Buckinghamshire, UK). Membranes were blocked with 5% 
milk in Tris-buffered saline with Tween (TBS-T) (Tris-buffered 
saline, 0.1% Tween-20) for 1 h at RT and then incubated with 
the primary antibody (rabbit anti-GPR84, rabbit anti-phospho-
Akt, rabbit anti-phospho-ERK or mouse anti-p65) diluted 
1:1,000 in 5% BSA/TBS-T overnight at 4°C. Next, membranes 
were incubated with an HRP-conjugated anti-rabbit secondary 
antibody for 1 h at RT. Protein bands were visualized by incuba-
ting the membranes for 5 min with Amersham ECL prime and 
subsequent exposure to X-ray film over a range of exposure times. 
β-actin, histone-H3, and tubulin were used as loading controls. 
For successive antibody incubations using the same membrane 
bound antibodies were removed with stripping buffer (Thermo 
Fisher Scientific). Full, uncropped blots can be found in Figure S7 
in Supplementary Material, where also shown that similar results 
were obtained using total ERK and total Akt antibodies rather 
than β-actin for loading controls.
ELISA
Measurement of TNFα, IL6, and CCL2 secreted protein levels 
in cell supernatants was performed by ELISA (R&D Systems) 
according to manufacturer’s instructions.
Immunofluorescence
For p-65 expression and location detection by immunofluo-
rescence, cells placed in a 4-well chamber-slide were fixed (4% 
paraformaldehyde) for 10 min at RT, permeabilized (0.5% Triton 
X-100 in PBS) for 10 min at 4°C, blocked with 4% BSA/PBS con-
taining 6% donkey serum, and incubated with mouse anti-p-65 
antibody diluted 1:100 in 4% BSA/PBS, overnight at 4°C. Cells 
were then incubated with donkey anti-mouse Alexa Fluor 488 
diluted 1:500 in 4% BSA/PBS for 1 h at RT. DAPI (4’,6-diamidino-
2-phenylindole) was used for nuclear counterstaining. The slide 
was mounted with Fluormount-G® and cells were visualized 
using a confocal microscope.
statistical analysis
All quantitative data are expressed as mean ± SEM of n independ-
ent biological replicates. Statistical significance was performed 
using a Student’s unpaired t-test, or one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparison post hoc 
test (Prism 7 GraphPad Software, San Diego, CA, USA). A P value 
of <0.05 was taken to be statistically significant.
resUlTs
Gpr84 expression is increased During 
acute inflammation
To assess the pattern of Gpr84 expression in mice during acute 
inflammation, we carried out an experimental model of endo-
toxemia. We administered 1 mg/kg LPS i.p. to male C57BL/6 
mice and sacrificed at 2 and 8 h. As shown in Figure 1, LPS 
injection significantly increased Gpr84 mRNA levels in 
mouse adipose tissue, bone marrow, brain, lung, kidney, and 
FigUre 1 | Gpr84 expression is increased in mouse tissues in acute inflammation. C57BL/6 male mice were injected i.p. with 0.1 mg/kg of LPS or PBS (controls). 
Animals were sacrificed at 2 and 8 h and Gpr84 expression was examined by q-PCR of the cDNA from mouse tissues. (a) Gpr84 mRNA levels at 2 h post PBS or 
LPS injection in adipose tissue, bone marrow, brain, and lung. (b) Gpr84 mRNA levels at 8 h post PBS or LPS injection in adipose tissue, bone marrow, brain, lung, 
kidney, and intestine. (c) Agarose gel electrophoresis of q-PCR products from mouse tissue cDNA of the 8 h endotoxemia experiment are shown. Products sizes 
are 139 bp for GPR84 and 72 bp for β-actin. Data presented as mean ± SEM. The number of animals is represented by dots in the graph. Statistical significance 
was assessed using a Student’s unpaired t-test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 versus PBS control group.
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intestine compared to PBS-injected control mice, both at 2 
(Figure  1A) and 8  h (Figures  1B,C). The highest levels of 
Gpr84 mRNA were found in the bone marrow. As there are 
no commercially available specific antibodies against GPR84 
(see Figure S1A in Supplementary Material), we were unable 
to confirm directly the Gpr84 mRNA pattern of expression 
at protein level. In order to identify the main cell population 
responsible for the increased Gpr84 expres sion, we performed 
FACS to sort monocytes, neutrophils, and total myeloid cells, 
excluding neutrophils/monocytes, from bone marrow isolated 
from mice treated with PBS or LPS. As shown in Figure 
S2 in Supplementary Material, only monocytes significantly 
increased Gpr84 mRNA expression in the bone marrow of 
LPS-treated mice.
M1 Pro-inflammatory Macrophages 
express high levels of Gpr84
Macrophages are key players during both acute and chronic 
inflammation. In order to investigate the expression of Gpr84 
in different human and murine macrophage populations, we 
first polarized cells into “M1-like” pro-inflammatory state or 
“M2-like” pro-resolution state. Gpr84 mRNA was significantly 
upregulated by LPS in all murine macrophage cell popula-
tions, including BMDMs, biogel-elicited macrophages, resident 
peritoneal macrophages, the cell line RAW 264.7 and microglia 
(Figures  2A–E). Similar results were observed with hMDMs 
(Figure 2F). In contrast, Gpr84 values were comparable to basal 
values in macro phages stimulated with IL-4. To further character-
ize macrophage Gpr84 expression, we challenged BMDMs with 
a range of inflammatory stimuli including several pathogen-
associated molecular patterns and selected cytokines for 2, 8, and 
16 h (Figures 2G–I). Addition of LPS and zymosan resulted in 
increased BMDM expression of Gpr84 at all time points, show-
ing a significant peak at 8 h. In contrast, IL-4 and IL-13 did not 
stimulate Gpr84 expression and, if anything, they downregulated 
receptor expression. Our results are in agreement with the pub-
lished literature, indicating that GPR84 is strongly upregulated 
in macrophages under pro-inflammatory conditions (11, 25). All 
of the experiments reported in Figure 2 were performed using a 
crude preparation of LPS that can signal via both TLR4 and TLR2. 
In Figure S3 in Supplementary Material, we compared activation 
of Gpr84 mRNA expression induced by two different preparations 
of LPS, one crude (cLPS) and a more pure preparation (pLPS). 
Both LPS preparations gave similar levels of Gpr84 induction at 
8 h to that seen with 300 ng ml−1 Pam3Cys, a TLP1/2 agonist. 
Taken together, our macrophage expression data show that high 
levels of Gpr84 mRNA expression can be induced via signaling 
via multiple TLRs.
Gpr84 expression is increased During 
chronic low-grade inflammation
It is known that chronic low-grade inflammation plays a key 
role in the pathogenesis of atherosclerosis and diabetes (26, 27). 
Thus, we aimed to evaluate the expression of the GPR84 
FigUre 2 | Gpr84 expression is highly expressed by M1 pro-inflammatory macrophages. (a–F) mRNA expression of GPR84 was analyzed by q-PCR of cDNA 
prepared from bone marrow-derived macrophages (BMDMs) (a), biogel-elicited macrophages (b), resident peritoneal macrophages (c), RAW 264.7 cells  
(D), microglia cells (e), and human monocyte-derived macrophages (hMDMs) (F) challenged with either LPS or IL-4 for 16 h. (g–i) mRNA expression of GPR84 
receptor was analyzed by q-PCR on BMDMs following exposure to TLR ligands and cytokines for 2 (g), 8 (h), and 16 (i) h. Error bars represent SEM of n = 2–4 
separate experiments. Statistical significance was assessed using one-way ANOVA with Dunnett’s multiple comparison post hoc test. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001 versus basal, #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 versus LPS.
7
Recio et al. GPR84 Enhances Inflammation
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1419
receptor under both hyperglycemic and dyslipidaemic conditions 
in mouse tissues and in cultured BMDMs. For in vivo diabetes 
studies, tissues were immediately harvested from NOD mice once 
classed as diabetic by glycosuria. Littermate age-matched NOD 
mice controls were those with no detectable glycosuria at the 
time of analysis. Gpr84 mRNA expression was found to be sig-
nificantly upregulated in the bone marrow, brain, and kidney of 
diabetic mice (Figures 3B–D). However, no significant changes 
in Gpr84 expression were observed in adipose tissue and lung 
(Figures 3A,E). In vitro, BMDMs grown in low glucose condi-
tions (5.5 mM) showed a significant increase in Gpr84 expression 
when stimulated with high (25  mM) d-glucose, but not with 
l-Glucose (Figure 3F).
Atherosclerosis is a chronic inflammatory disease and to 
evaluate the expression of GPR84 in this condition, ApoE−/− mice 
were fed a HFD for 6 and 12  weeks, then sacrificed and tis-
sues collected. Male ApoE−/− mice fed a chow diet were used as 
controls. ApoE−/− HFD groups had significantly higher levels 
of Gpr84 mRNA in their aortae compared to controls, at both 
6 and at 12  weeks of dietary manipulation. These levels were 
significantly higher after 12 weeks compared to 6 weeks of HFD 
(Figures 3G,H). However, no differences between groups were 
detected in the expression of Gpr84 in other tissues including 
adipose tissue, brain, kidney, and lung (data not shown). In 
parallel, in vitro studies were performed using hMDMs, which 
showed approximately twofold increase in Gpr84 expres-
sion when challenged with oxidized LDL particles for 48  h 
(Figure 3I).
Taken together, our results suggest that the GPR84 receptor 
could play a role in the inflammatory process that underlies 
FigUre 3 | Gpr84 expression is enhanced under hyperglycemia and hypercholesterolemia conditions. (a–e) Non-obese diabetic mice were assessed for  
diabetes by blood glucose test and, once diagnosed diabetic, they were sacrificed and Gpr84 expression was examined by q-PCR in the cDNA from adipose  
tissue (a), bone marrow (b), brain (c), kidney (D), and lung (e). Data are presented as mean ± SEM of n = 4–5 mice per group. Statistical significance was 
assessed using a Student’s unpaired t-test. *P ≤ 0.05 versus control group. (F) mRNA expression of GPR84 receptor was analyzed by qPCR on bone marrow-
derived macrophages grown in low glucose media (5 mM) following exposure to high glucose shock (30 mM) for 4 h. Error bars represent SEM of n = 4 separate 
experiments. Statistical significance was assessed using one-way ANOVA with Dunnett’s multiple comparison post hoc test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 
versus basal; #P ≤ 0.05, ##P ≤ 0.01 versus d-glucose. (g,h) ApoE−/− mice were fed either high-fat diet or chow diet. Animals were sacrificed at 6 (g) and 12  
(h) weeks of diet and Gpr84 expression was examined by q-PCR of cDNA prepared from aortic tissue. Data are presented as mean ± SEM of 4–5 mice per  
group. Statistical significance was assessed using a Student’s unpaired t-test. *P ≤ 0.05 versus ApoE−/− + chow diet. (i) mRNA expression of GPR84 receptor  
was analyzed by q-PCR of human monocyte-derived macrophages challenged with oxLDL for 48 h. Error bars represent SEM of n = 5 separate experiments. 
Statistical significance was assessed using a Student’s unpaired t-test. *P ≤ 0.05 versus vehicle.
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diabetes and atherosclerosis. Further studies are necessary to 
elucidate the specific function of the GPR84 receptor in these 
pathologies.
6-OaU is a specific synthetic ligand  
of gPr84 in Primary Macrophages
Because of the lack of consensus about whether MCFAs are 
the true physiological ligands of GPR84, several studies have 
south to develop new small molecule agonist compounds. 
One of these, 6-OAU, has been shown to activate GPR84 with 
good potency and specificity compared to MCFAs and other 
surrogate agonists such as diindolylmethane (DIM) (13). We, 
therefore, performed a cAMP assay in CHO cells transfected 
with the human GPR84 receptor (hereafter referred to as 
GPR84-CHO) to compare the potency of 6-OAU and capric 
acid on the activation of GPR84. When activated, GPR84 binds 
to the Gαi protein, thus inhibiting the adenylate cyclase enzyme 
and in turn abrogating the production of intracellular cAMP. 
As reported in Figure  4A, 6-OAU showed an EC50 =  14  nM 
inhibiting the production of cAMP and, being 57 times more 
potent than capric acid. 6-OAU showed no inhibition of cAMP 
in non-transfected CHO cells (data not shown).
In order to corroborate these findings in primary macro-
phages, we employed an electrical impedance assay that allows 
measurement of cytoskeletal dynamics in real-time following 
GPCR activation (20). For these experiments and all the 
signaling assays hereafter, BMDMs were pre-treated with LPS 
in order to place cells in an inflammatory environment and 
promote an increased expression of GPR84. We first assessed 
the effect of the three leading MCFAs that have been claimed 
as physiological ligands of GPR84, namely lauric acid, capric 
acid, and undecanoic acid. BMDMs that had been pre-treated 
with LPS were challenged with lauric, capric, and undecanoic 
acids and changes in the electrical impedance after agonist 
FigUre 4 | 6-OAU is a potent and specific surrogate agonist of GPR84. (a) Intracellular cyclic AMP levels were measured in CHO-GPR84 cells following forskolin 
stimulation and incubation with 6-OAU or capric acid. Data are represented as the mean ± SEM of the percentage of the response to forskolin in the absence of 
agonists from n = 3 independent experiments. (b–D) A real-time cell impedance assay was performed to measure changes in cell impedance in response to 
agonists. (b) Bone marrow-derived macrophages (BMDMs) (50,000 cells/well) were added 0.1 µg/ml LPS and were seeded into a 96-well E-plate allowed to adhere 
for 16 h. Afterward, cells were treated with vehicle (0.3% DMSO), 10 nM C5a, 10 µM capric acid, 10 µM lauric acid, or 10 µM undecanoic acid. CI measurements 
were taken every 10 s after compound addition. LPS (0.1 µg/ml) was added to WT BMDMs (c) and GPR84−/− BMDMs (D) seeded in a 96-well E-plate for 16 h 
before agonist addition. Cells were stimulated with either vehicle (0.3% DMSO), 10 nM C5a, or 6-OAU at the doses indicated in the legend. CI measurements were 
taken every 10 s after compound addition. Curves represent changes in cell index after agonist addition. Representative figures from n = 4 independent biological 
experiments are shown.
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addition were detected and represented as Cell Index response 
curves. As shown in Figure  4B, none of the three MCFAs 
caused a similar BMDM response curve to that seen with C5a, 
a potent macrophage stimulus used as positive control and 
acting through a different receptor. Indeed, the macrophage 
response to capric acid was comparable to vehicle. We then 
tested the synthetic GPR84 agonist 6-OAU in BMDM signal-
ing. Different concentrations of 6-OAU were added to LPS 
pre-treated BMDMs, and as shown in Figure 4C, stimulation of 
WT BMDMs with 6-OAU caused a rapid increase in cell index, 
which correlates with increased cell spreading. The maximal 
response of BMDMs took place when adding 1–10 µM 6-OAU 
and was, even higher than the response of BMDMs to C5a. In 
contrast, no response was observed when adding any dose of 
6-OAU to GPR84−/− cells, where signals were at similar levels 
to the vehicle (Figure 4D). However, GPR84−/− cell responses 
to C5a were the same as WT macrophages. Thus, our data 
indicate that 6-OAU is a specific agonist of GPR84 and, as 
such, induces a biological response in primary macrophages.
activation of gPr84 Potentiates aKT  
and erK Phosphorylation and p65  
nuclear Translocation in WT, but not  
in gPr84−/− bMDMs
To investigate the potential functional significance of GPR84 
activation in macrophages during the inflammatory response, 
we focused our attention on the main intracellular signaling cas-
cades involved in key macrophage processes including migra-
tion, adhesion, and phagocytosis. We, therefore, analyzed the 
activation of AKT, ERK, and the NFκB subunit p65 in BMDMs 
pre-treated with 0.1  µg/ml LPS before adding 1  µM 6-OAU 
for different periods. As shown in Figure  5A, an increase in 
phosphorylation of AKT was observed when compared to 
vehicle in WT BMDMs just 5–10  min after 6-OAU addition. 
This increased activation returned to basal levels after 30 min of 
treatment with the agonist. Similarly, a peak of ERK phospho-
rylation was seen after 10 min of 6-OAU incubation. However, 
ERK revealed a different activation kinetic, as another peak of 
FigUre 5 | GPR84 signaling activates AKT, ERK, and NFκβ in WT, but not in GPR84−/− macrophages. (a) Bone marrow-derived macrophages (BMDMs) were 
treated with 0.1 µg/ml LPS for 2 h before stimulated with either vehicle (0.3% DMSO) or 1 µM 6-OAU for 1, 5, 10, 30, and 60 min. Cell lysates were prepared  
and western blotting conducted for either phosphorylated Akt (P-AKT) or ERK 1/2 (P-ERK), followed by stripping and re-staining for β-actin as a loading control. 
Representative images from n = 3 independent experiments are shown. (b) BMDMs were treated with LPS (0.1 µg/ml) for 2 h before stimulation with vehicle  
(0.3% DMSO) or 1 µM 6-OAU for 30 min followed by p65 staining. Confocal microscopy images are illustrative of two separate experiments. (c) BMDMs were 
treated with LPS (0.1 µg/ml) for 2 h before stimulation with either vehicle (0.3% DMSO) or 1 µM 6-OAU for 5, 10, 30, and 60 min. Western blotting for p65 was 
performed using samples from cytoplasmic and nuclear fractions of cell lysates, followed by stripping and re-staining for histone-3 in the nuclear fraction and 
α-tubulin in the cytoplasmic fraction as a loading control. Representative images from n = 3 independent experiments are shown.
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phosphorylation was observed at 60 min of agonist exposure. 
In contrast, when the same experiment was performed in 
GPR84−/− BMDMs, no significant differences in the activation 
of AKT and ERK were seen when cells were treated with 6-OAU. 
For assessing the differential expression of the NFκB subunit 
p65 in BMDMs, the cellular compartments were separately 
analyzed by immunofluorescence and Western blot. When 
activated by phosphorylation, NFκB subunits translocate to the 
nucleus and activate the transcription of inflammatory genes 
(28). As shown in Figure 5B, the distribution of p65 was more 
concentrated to the nucleus when LPS-primed cells were treated 
with 6-OAU compared to vehicle, indicating NFκB activation. 
Western blot data confirmed that 10 min of 6-OAU treatment 
was the time point with maximal levels of p65 nuclear transloca-
tion (Figure 5C).
gPr84 activation enhances Pro-
inflammatory cytokine and chemokine 
expression in Macrophages
One of the major macrophage functions in inflammation is to 
modulate the immune response by production of cytokines, 
chemokines, and other inflammatory mediators (29). Since 
increased levels of signaling pathway activation were found in 
BMDMs following 6-OAU treatment, we next tested whether 
there was increased expression of inflammatory mediators after 
GPR84 activation in macrophages. We evaluated the expression 
of the cytokines TNFα, IL-6, and IL-12b. We also analyzed the 
expression of the chemokines CCL2, CCL5, and CXCL1, the 
scavenger receptor FCγRI, and the adhesion molecule ICAM-1 
(30). Measurement of these mediators by qRT-PCR showed 
FigUre 6 | GPR84 activation enhances pro-inflammatory mediator expression in macrophages. (a,c,e) Bone marrow-derived macrophages (BMDMs) were 
treated with 0.1 µg/ml LPS for 2 h before stimulation with vehicle (0.3% DMSO) or 1 µM 6-OAU for 30, 60, 90, 120, and 240 min. mRNA expression of Tnfα  
(a), Il-6 (c), and Ccl2 (e) was analyzed by q-PCR of WT and GPR84−/− BMDMs. Secreted protein levels of TNFα (b), IL-6 (D), and CCL2 (F) were measured  
by ELISA. Data presented as mean ± SEM of n = 4–6 separate experiments. Statistical significance was assessed using one-way ANOVA with Dunnett’s  
multiple comparison post hoc test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 versus vehicle.
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that 6-OAU-mediated-GPR84 activation promoted enhanced 
expression of inflammatory cytokines and chemokines in LPS 
pre-treated WT BMDMs compared with vehicle-treated cells. 
Tnfα levels progressively increased with time (Figure 6A), while 
Il-6 (Figure 6C), Ccl2 (Figure 6E), Il-12b, Ccl5, Cxcl1, FcγRI, and 
Icam-1 (Figures S4A–E in Supplementary Material) levels rapidly 
increased at 30–60  min post 6-OAU addition and remained 
elevated at later time points. However, as shown in Figure S5 
in Supplementary Material, naïve WT BMDMs—without LPS 
pre-treatment—did not show an upregulation of inflammatory 
gene expression mediated by 6-OAU alone, most likely explained 
by the low expression levels of the GPR84 receptor. Importantly, 
FigUre 7 | GPR84 antagonist abrogates the enhanced inflammatory response mediated by 6-OAU. (a) Intracellular cyclic AMP levels were measured in 
CHO-GPR84 cells pre-treated with the antagonist followed by forskolin and 6-OAU stimulation. Data are represented as the mean ± SEM of the percentage of  
the response to forskolin in the absence of agonists n = 3 independent experiments. (b–h) Bone marrow-derived macrophages were treated with LPS (0.1 µg/ml) 
for 2 h before pre-treatment with vehicle (0.3% DMSO), 10 µM antagonist for 30 min, or 200 ng/ml Pertussis toxin for 90 min. Afterward cells were stimulated with 
either vehicle (0.3% DMSO) or 1 µM 6-OAU for either 10′ for protein isolation or 1 h for RNA extraction. (b) Cell lysates were prepared and western blotting 
conducted for either phosphorylated Akt (P-AKT) or ERK 1/2 (P-ERK), followed by stripping and re-staining for β-actin as a loading control. Representative images 
from n = 3 independent experiments. (c–h) mRNA expression of Tnfα (c), Il-6 (D), Il-12 (e), Ccl5 (F), Ccl2 (g), and Cxcl1 (h) was analyzed by q-PCR. Data are 
presented as mean ± SEM of n = 4–7 separate experiments. Statistical significance was assessed using one-way ANOVA with Dunnett’s multiple comparison 
post hoc test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 versus vehicle; #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 versus 6-OAU.
12
Recio et al. GPR84 Enhances Inflammation
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1419
GPR84−/− BMDMs did not show any upregulated gene expression 
when treated with 6-OAU at any time point, thus indicating that 
all the effects found in WT  cells stimulated with 6-OAU were 
GPR84-mediated (Figures 6A,C,E).
In addition, not only gene expression but also protein levels 
measured by ELISA were enhanced post GPR84 activation 
(Figures  6B,D,F). Whereas TNFα and CCL2 protein secretion 
peaked after 4 h post 6-OAU addition, IL-6 showed highest levels 
at just 1 h. Taken together, our data show that pro-inflammatory 
mediator production in LPS-primed macrophages is rapidly 
upregulated upon GPR84 activation by a synthetic agonist.
gPr84 blockade With a selective 
antagonist counteracts the enhanced 
inflammatory effects Mediated by 6-OaU 
in Macrophages
To test the hypothesis that blocking the activation of GPR84 could 
be a potential anti-inflammatory strategy in different inflam-
matory diseases, we used a reported GPR84 antagonist from 
the patent literature (Galapagos NV Company), the chemical struc-
ture of which is shown in Figure 7A. We first assessed the potency 
and specificity of the antagonist using GPR84-CHO cells in 
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the cAMP assay. Our data show that the antagonist effectively 
inhibited the action of 6-OAU in decreasing cAMP produc-
tion in GPR84-CHO cells (Figure  7A). To test this antagonist 
compound’s inhibition of the pro-inflammatory effects of GPR84 
activation in macrophages, LPS pre-treated BMDMs were incu-
bated with 10  µM antagonist for 30  min before adding 1  µM 
6-OAU. Protein analysis by Western Blot showed that the GPR84 
antagonist partially blocked the phosphorylation of AKT and 
ERK induced by 6-OAU (Figure 7B). Likewise, GPR84 blockade 
reduced the expression of TNFα, IL-6, IL12b, CCL2, CCL5, and 
CXCL1 in BMDMs (Figures 7C–H). PTX was used as a positive 
control for the inhibition of GPR84 signaling.
6-OaU Mediated—gPr84 activation 
Promotes Migration, bacterial adhesion, 
and Phagocytosis in Macrophages, effects 
That are inhibited by a gPr84 antagonist
Having shown that LPS-primed BMDMs treated with a GPR84- 
specific agonist displayed an exacerbated inflammatory res-
ponse, we next sought to investigate if these changes in protein 
and gene expression are associated with different functional 
behaviors in macrophages. During the inflammatory response, 
macrophages migrate to sites of inflammation and, adhere to 
particulate debris, which is removed by phagocytosis (31). 
We, therefore, performed different assays in order to evaluate 
changes in macrophage functionality following GPR84 activa-
tion with its agonist 6-OAU.
As shown in Figures  8A,B, we carried out a scratch assay 
on BMDM monolayers, which revealed that 6-OAU-mediated 
GPR84 activation potentiated BMDM migration stimulated by 
C5a. However, this only happened in the presence of C5a, thus 
indicating that GPR84 signaling enhances but does not mediate 
macrophage migration directly. We, therefore, evaluated 6-OAU 
as a macrophage chemoattractant in a well-validated real-time 
chemotaxis assay. 6-OAU displayed no chemotactic properties 
when compared to C5a at any of the tested doses in BMDMs 
(Figure S6 in Supplementary Material).
In a live bacteria phagocytosis assay, it was found that mac-
rophages pre-treated with 6-OAU showed an increased adhesion 
of GFP-labeled E. coli to the cell surface (Figure 8C). In contrast, 
cells pre-treated with the GPR84 antagonist before exposure to 
6-OAU showed a similar number of adherent bacteria to vehicle 
treated cells.
To further assess the phagocytic activity of macrophages, we 
performed a pHrodo-conjugated E. coli phagocytosis assay using 
the IncuCyte ZOOM real-time cell imaging system as described 
previously (32). By taking images of the green fluorescence emit-
ted by bacteria once inside the phagolysosome, we found that 
6-OAU significantly enhanced phagocytosis in WT BMDMs, 
but not in GPR84−/− BMDMs (Figures 8D,E). Furthermore, as 
shown in Figures 8F,G, these effects were abolished when cells 
were pre-treated with the GPR84 antagonist.
In a third macrophage phagocytosis assay, we examined macro-
phage uptake of opsonized polystyrene beads. In this bead 
phagocytosis assay, we found that 6-OAU mediated-GPR84 
activation enhanced the number of cells phagocytosing beads, 
when compared to vehicle-treated cells (Figures 8H,I). However, 
no significant differences were observed in the number of beads 
per cell within those cells that had phagocytosed beads (data not 
shown).
DiscUssiOn
GPR84 is a metabolic GPCR the expression of which has been 
previously described in leukocytes (11). However, potential roles 
for GPR84 signaling in modulating the inflammatory response 
have not been fully explored. In the present study, we show that 
the GPR84 receptor is upregulated in murine macrophages 
under inflammatory conditions in vitro, in hMDMs ex vivo, and 
in mouse models of endotoxemia and immuno-metabolic stress 
in vivo. We show that the synthetic GPR84 agonist 6-OAU selec-
tively activates the GPR84 receptor in WT, but not in GPR84−/− 
macrophages, displaying increased potency as a GPR84 agonist 
than the claimed physiological ligands MCFAs. Activation of 
GPR84 by 6-OAU enhances the inflammatory response in mac-
rophages by increasing the phosphorylation of Akt and, ERK as 
well as the nuclear translocation of NFκB, causing an increase 
in expression of key inflammatory cytokines and chemokines. 
Our experiments show that 6-OAU-mediated-GPR84 activa-
tion promotes macrophage migration, bacterial adhesion, and 
phagocytic activity of BMDMs, but not chemotaxis. Finally, 
specific antagonism of GPR84 attenuates the enhanced inflam-
matory responses mediated by 6-OAU.
It has been previously reported that leukocyte GPR84 recep-
tor expression is upregulated after LPS stimulation in  vitro  
(11, 13). We report that in a murine model of low-dose endo-
toxemia, all tissues assessed displayed a significantly increased 
expression of Gpr84 at 2 and 8  h post LPS injection. Bone 
marrow was the tissue showing the highest levels of receptor 
expression, which is in accordance with the GPR84 receptor 
being upregulated in immune cells in the context of acute 
inflammation (13). Specifically, we have shown that within 
the bone marrow, monocytes are the cell type accounting for 
the large increase in Gpr84 expression after LPS treatment. We 
showed that not only BMDMs but also many other macrophage 
populations including biogel-elicited macrophages, resident 
peritoneal macrophages, the murine macrophage cell line 
RAW 264.7, mouse microglia, and human MDM, expressed 
higher levels of Gpr84 when stimulated with LPS. However, we 
showed that this response is not unique and specific of TLR4 
receptor, since other stimuli including zymosan (TLR2 and 
Dectin-1 specific agonist) and Pam3CysK (TLR2 specific ago-
nist) also significantly activated Gpr84 expression. In contrast, 
all macrophage populations tested showed lower expression of 
the receptor after IL-4 treatment. This expression pattern sug-
gests a possible role for GPR84 in M1 polarized macrophages. 
However, when we evaluated the expression of BMDM Gpr84 
mRNA after LPS addition with the cytokine IFNγ (the classic M1 
polarizing stimulus), we saw a consistently lower level of Gpr84 
mRNA expression. It is unfortunate that we cannot study GPR84 
protein expression in macrophages directly due to the lack of 
specificity of all commercially available anti-GPR84 antibodies 
tested (Figure S1 in Supplementary Material). In their review of 
FigUre 8 | Continued
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FigUre 8 | 6-OAU mediated—GPR84 activation promotes macrophage migration, bacterial adhesion, and phagocytosis. Bone marrow-derived macrophages 
(BMDMs) were treated with LPS (0.1 µg/ml) for 2 h before stimulation with vehicle (0.3% DMSO) or 1 µM 6-OAU for 1 h. In inhibition experiments, cells were 
pre-treated with 10 µM antagonist before stimulation. (a,b) A near confluent monolayer of BMDMs was scratched and 10 nM C5a or vehicle was added to cells.  
(a) Quantification of the number of cells that had migrated into the scratch at t = 24 h. Data are presented as mean ± SEM of n = 4 separate experiments. 
Statistical significance was assessed using two-way ANOVA with Tukey’s multiple comparison test. (b) Images from the IncuCyte imaging software at 20× 
magnification showing cells invading the scratch after 24 h monitoring. Representative images from n = 4 independent experiments are shown. (c) E. coli strain 
DH5-α bacteria adherence to the macrophage surface were measured following the protocol given in the Section “Materials and Methods” and expressed as  
CFU per milliliter after BMDM lysis. (D–g) BMDMs were incubated with pH-rodo Green E. coli bioparticles (0.1 mg/ml), and fluorescence emission was measured  
in the IncuCyte imaging platform every 15 min for 4 h at 37°C. (D,e,g) Quantification of the green object counts per well (p96-well plate) in WT (D) and GPR84−/−  
(e) BMDMs. (g) Green object counts per well (p24-well plate) in WT BMDMs under inhibitory conditions. Data are presented as mean ± SEM from n = 4 biological 
replicates in technical duplicate. (F) Representative images from the IncuCyte software from one of n = 4 separate experiments are shown. Scale bar 200 µm.  
(h,i) BMDMs were incubated with opsonized 3 µm polystyrene beads for 1 h at 37°C and then fixed and stained with safranin. Twenty images per well were  
taken and bead numbers were quantified by an observer blind to treatment group. Data are presented as the number of cells with beads inside divided by the  
total number of cells per image. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 versus vehicle.
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the M1 M2 macrophage differentiation paradigm, Martinez and 
Gordon explicitly define macrophages treated with endotoxin as 
a class of macrophages distinct from “classic” M1 macrophages 
induced by treatment with LPS and IFNγ (33). Monoclonal 
antibodies that specifically recognize GPR84 could be a good 
marker for a population of activated macrophages distinct from 
M1 macrophages at sites of inflammation in vivo.
Considering that GPR84 has been claimed as a metabolic 
GPCR, we wanted to evaluate how its expression was regulated 
in two important metabolic diseases where inflammation plays 
a key role: diabetes and atherosclerosis (Figure 3). The pattern 
of Gpr84 expression in tissues of NOD mice that had recently 
become diabetic is consistent with pathological changes in 
hematopoiesis (bone marrow) and the kidney. Increased 
brain expression Gpr84 mRNA is interesting but difficult to 
interpret without looking at RNA and protein expression in 
mouse disease models and human tissue. However, this cor-
relates with the previously reported high Gpr84 expression in 
microglia in different disease models such as endotoxemia, 
experimental autoimmune encephalomyelitis, Alzheimer, and 
neuronal injury (34–36). Gpr84 mRNA levels where elevated 
in aortic tissue of ApoE−/− mice fed a high fat diet rather than a 
regular chow diet (Figures 3G,H) strongly suggesting elevated 
Gpr84 expression in atherosclerotic lesions. We speculate 
that the source of the increased Gpr84 content could be from 
infiltrating macrophages into the lesion. Furthermore, our 
data showing that macrophages stimulated with oxidized LDL 
particles expressed high levels of Gpr84 suggest that infiltrating 
macrophages could be involved in the atherosclerotic plaque 
progression (26). Our demonstration that synthetic agonists 
of GPR84 activate pro-inflammatory signaling and cytokine 
release in already activated macrophage populations suggests 
that detailed examination of GPR84 expression and signaling 
is merited in murine and human atherosclerosis. Given the lack 
of macrophage signaling in response to capric acid seen in our 
cell impedance assays (Figure 4B), atherosclerotic lesions may 
be a good place to start looking for physiological ligands active 
at this enigmatic receptor.
In the continuing debate over the true physiological agonist(s) 
for the GPR84 receptor, researchers are placing increased reli-
ance on chemical tool compounds to explore the role of GPR84 
signaling in leukocyte biology (37). In this study, we chose to 
use the synthetic agonist 6-OAU rather than two other GPR84 
synthetic agonists embelin (38, 39) and DIM (12, 15). This 
was because 6-OAU is so far, the most specific GPR84 agonist. 
Embelin has been reported to potently inhibit the X-linked 
inhibitor of apoptosis protein in cancer cells (40–42) and has 
been shown to bind the Adenosine A3 receptor and CXCR2 
(38). Diindolylmethane 2 (DIM) is an agonist at the cannabinoid 
receptor 2 (CB2) in macrophages (43).
When exploring the biological effects of GPR84 agonists in 
macrophage biology, it is important to ensure that any effects 
seen with tool compounds are specific to the GPR84 receptor. 
We demonstrated the specificity of 6-OAU: biologically, using 
macrophages from GPR84−/− mice, and chemically using the 
reported Galapagos GPR84 antagonist. We show for the first 
time that 6-OAU signaling is completely ablated in GPR84−/− 
BMDMs in a number of different signaling assays including cell 
impedance sensing (Figure  4D), AKT, and ERK phosphoryla-
tion (Figure 5A) NFκB activation (Figures 5B,C), cytokine and 
chemokine expression (Figure 6), and macrophage phagocytosis 
(Figure  8E). These experiments cannot exclude the possibility 
that 6-OAU signals at other GPCRs expressed in macrophages, 
but they clearly demonstrate that all of 6-OAU’s biological effects 
on macrophages are lost when the GPR84 receptor is deleted. 
A similar demonstration of the GPR84 specificity of embelin 
and DIM is currently missing. We have shown that the GPR84 
antagonist blocks the biological effects of 6-OAU in transfected 
GPR84-CHO cells (Figure 7A). We have further demonstrated 
the antagonist’s potential utility to target GPR84 in AKT and 
ERK phosphorylation (Figure  7B) cytokine and chemokine 
expression (Figures 7C–H), bacterial adhesion (Figure 8C), and 
macrophage phagocytosis (Figures 8F,G).
Activation of the GPR84 receptor in microglia by embelin has 
been shown to induce cytoskeletal changes that was interpreted 
as “membrane ruffling” despite an absence of live cell imaging 
(39). We report for the first time the ability of 6-OAU to enhance 
macrophage phagocytosis of pHrodo labeled E. coli bioparticles, 
an effect that is lost in GPR84−/− macrophages and macrophages 
treated with a GPR84 antagonist. 6-OAU treatment enhances 
macrophage phagocytosis of opsonized polystyrene beads and 
doubles E. coli adhesion to macrophages (Figure 8C). Analysis 
of BMDM gene expression following 6-OAU treatment shows 
significantly enhanced FcγR1 mRNA expression within 30 min, 
which could contribute to the observed enhanced macrophage 
binding to bacteria (Figure S2D in Supplementary Material).
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In our study, we have focused on GPR84 expression and func-
tion in murine and human macrophage populations. Our Gpr84 
mRNA expression studies could be extended to dendritic cells, 
lymphocytes, and neutrophils, but such studies would be more 
useful if they could be combined with GPR84-specific antibody 
reagents or fluorescently labeled GPR84 agonist compounds. 
Although 6-OAU has been used in vivo in rats, no pharmacoki-
netic or pharmacodynamic data are available for this GPR84 
agonist (13), so in vivo delivery of GPR84 agonists in mice must 
await a full evaluation of GPR84-specific compounds in wild-type 
and Gpr84−/− mice.
Our detailed studies confirm that macrophage Gpr84 mRNA 
expression is significantly upregulated by pathogen molecular 
patterns including LPS, Pam3CysK, and zymosan. Our func-
tional studies using the synthetic ligand 6-OAU show that 
murine macrophages pre-treated with LPS exhibit enhanced 
inflammatory signaling following GPR84 activation resulting 
in increased expression of key inflammatory cytokines and 
chemokines. In contrast, macrophages do not respond signifi-
cantly to 6-OAU in the absence of LPS pre-treatment. This can 
be explained by the fact that expression levels of Gpr84 mRNA 
in basal conditions are relatively low compared to those seen in 
LPS conditions, hence limiting GPR84 agonist signaling via its 
cognate receptor and induction of downstream signaling.
In contrast to previous published work, we find no evidence 
that GPR84 agonists act as chemoattractants for murine mac-
rophages. Rather, 6-OAU enhances macrophage phagocytosis 
of opsonized and unopsonised targets, an effect that is lost in 
Gpr84−/− cells and in macrophages pre-treated with a published 
GPR84 antagonist.
Our novel findings are consistent with a model in which GPR84 
acts as a receptor that can amplify macrophage inflammatory 
responses at sites of inflammation and hence could represent an 
interesting target for the development of novel anti-inflammatory 
or antiatherogenic therapeutics.
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